Merck Reaches Record Securities Settlement over Cholesterol Drug Disclosures

Merck & Co. made history on Thursday, but maybe not the way the company and its lawyers at Paul Weiss would have liked. Ending five years of litigation less than three weeks before a scheduled trial, the pharma giant announced that it will pay $688 million to settle a pair of related securities fraud class actions over the drug Vytorin.

This article requires premium access

This article requires premium access to The AmLaw Litigation Daily. Please sign in or subscribe to read the full text.